Key clinical point: Adding aspirin to DOAC therapy for secondary prevention of VTE or prevention of stroke associated with NVAF may increase bleeding risk.
Major finding: Bleeding event rate per 100 patient years: 39.50 vs. 32.32 with DOAC + aspirin vs. DOAC alone.
Study details: A registry-based cohort study of 639 patients and 639 controls.
Disclosures: Dr. Schaefer reported having no disclosures.
Schaefer J et al. ASH 2019. Abstract 787.